Influence of active efflux transport on the distribution of targeted agents to brain tumors

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Unknown venue

• Publication date

  2014-07-01

• Fields of study

  Medicine

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• GBM's multifaceted landscape: highlighting regional and microenvironmental heterogeneity.

  2014cited by this paper
• Fighting fire with fire: the revival of thermotherapy for gliomas.

  2014cited by this paper
• Ultrasound-mediated blood-brain barrier disruption for targeted drug delivery in the central nervous system

  2014cited by this paper
• Targeting the PI3K/AKT/mTOR signaling pathway in glioblastoma: novel therapeutic agents and advances in understanding

  2013cited by this paper
• Coordinate activation of Shh and PI3K signaling in PTEN-deficient glioblastoma: new therapeutic opportunities

  2013cited by this paper
• Effect of P-Glycoprotein and Breast Cancer Resistance Protein Inhibition on the Pharmacokinetics of Sunitinib in Rats

  2013cited by this paper
• A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer.

  2013cited by this paper
• Development of PI3K inhibitors: lessons learned from early clinical trials

  2013influential reference
• A phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer

  2013cited by this paper
• Medicinal Chemistry Based Approaches and Nanotechnology‐Based Systems to Improve CNS Drug Targeting and Delivery

  2013cited by this paper
• Pharmacokinetic Assessment of Efflux Transport in Sunitinib Distribution to the Brain

  2013influential reference
• Brain metastases from renal cell carcinoma in the era of tyrosine kinase inhibitors.

  2013cited by this paper
• Combinatorial antitumor effect of HDACs and the PI3K-Akt-mTOR pathway inhibition in a Pten deficient model of prostate cancer

  2013cited by this paper
• Intrathecal Drug Delivery (ITDD) systems for cancer pain

  2013cited by this paper
• Implanted Carmustine Wafers Followed by Concomitant Radiochemotherapy to Treat Newly Diagnosed Malignant Gliomas: Prospective, Observational, Multicenter Study on 92 Cases

  2013cited by this paper
• Function of the Blood-Brain Barrier and Restriction of Drug Delivery to Invasive Glioma Cells: Findings in an Orthotopic Rat Xenograft Model of Glioma

  2013influential reference
• Bayesian Approach to Estimate AUC, Partition Coefficient and Drug Targeting Index for Studies with Serial Sacrifice Design

  2013cited by this paper
• Vascular Endothelial Growth Factor Receptor 2 (VEGFR-2) Plays a Key Role in Vasculogenic Mimicry Formation, Neovascularization and Tumor Initiation by Glioma Stem-like Cells

  2013cited by this paper
• Sunitinib LC–MS/MS Assay in Mouse Plasma and Brain Tissue: Application in CNS Distribution Studies

  2013cited by this paper
• Phase II study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiforme.

  2013cited by this paper
• Dual mTORC1 and mTORC2 inhibitor Palomid 529 penetrates the Blood–Brain Barrier without restriction by ABCB1 and ABCG2

  2013cited by this paper
• Biopsy validation of 18F-DOPA PET and biodistribution in gliomas for neurosurgical planning and radiotherapy target delineation: results of a prospective pilot study.

  2013influential reference
• VEGF Promotes Proliferation of Human Glioblastoma Multiforme Stem-Like Cells through VEGF Receptor 2

  2013cited by this paper
• Phase I study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528

  2013cited by this paper
• Combined Targeting of mTOR and AKT Is an Effective Strategy for Basal-like Breast Cancer in Patient-Derived Xenograft Models

  2013cited by this paper
• Combined temozolomide and sunitinib treatment leads to better tumour control but increased vascular resistance in O6-methylguanine methyltransferase-methylated gliomas.

  2013cited by this paper
• Glioblastoma, a Brief Review of History, Molecular Genetics, Animal Models and Novel Therapeutic Strategies

  2012cited by this paper
• Intravitreal aflibercept injection for neovascular (wet) age-related macular degeneration

  2012cited by this paper
• Targeting the PI3K Pathway in the Brain—Efficacy of a PI3K Inhibitor Optimized to Cross the Blood–Brain Barrier

  2012influential reference
• The addition of Sunitinib to radiation delays tumor growth in a murine model of glioblastoma

  2012cited by this paper
• Recurrent anaplastic meningioma treated by sunitinib based on results from quantitative proteomics

  2012cited by this paper
• Brain Distribution of Cediranib Is Limited by Active Efflux at the Blood-Brain Barrier

  2012cited by this paper
• PDGF and PDGF receptors in glioma

  2012cited by this paper
• Brain accumulation of sunitinib is restricted by P‐glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration

  2012influential reference
• Concurrent blood-brain barrier opening and local drug delivery using drug-carrying microbubbles and focused ultrasound for brain glioma treatment.

  2012cited by this paper
• Intranasal administration: a potential solution for cross-BBB delivering neurotrophic factors.

  2012cited by this paper
• Platelet-derived growth factor receptors differentially inform intertumoral and intratumoral heterogeneity.

  2012influential reference
• A phase I/II trial of vandetanib for patients with recurrent malignant glioma.

  2012cited by this paper
• Molecular markers of glioma: an update on recent progress and perspectives

  2012cited by this paper
• Co-administration strategy to enhance brain accumulation of vandetanib by modulating P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp1/Abcg2) mediated efflux with m-TOR inhibitors.

  2012cited by this paper
• Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway.

  2012cited by this paper
• A prospective phase II single-institution trial of sunitinib for recurrent malignant glioma

  2012cited by this paper
• Enhanced brain accumulation of pazopanib by modulating P-gp and Bcrp1 mediated efflux with canertinib or erlotinib.

  2012cited by this paper
• The design and identification of brain penetrant inhibitors of phosphoinositide 3-kinase α.

  2012influential reference
• Quantitative Proteomics of Transporter Expression in Brain Capillary Endothelial Cells Isolated from P-Glycoprotein (P-gp), Breast Cancer Resistance Protein (Bcrp), and P-gp/Bcrp Knockout Mice

  2012cited by this paper
• Sunitinib in advanced pancreatic neuroendocrine tumors: latest evidence and clinical potential

  2012cited by this paper
• Focused ultrasound disruption of the blood-brain barrier: a new frontier for therapeutic delivery in molecular neurooncology.

  2012cited by this paper
• Inhibition of PI3K-Akt-mTOR signaling in glioblastoma by mTORC1/2 inhibitors.

  2012cited by this paper
• Active Efflux of Dasatinib from the Brain Limits Efficacy against Murine Glioblastoma: Broad Implications for the Clinical Use of Molecularly Targeted Agents

  2012cited by this paper
• Challenges in drug delivery to tumors of the central nervous system: an overview of pharmacological and surgical considerations.

  2012cited by this paper
• Adult glioblastoma multiforme survival in the temozolomide era: A population‐based analysis of Surveillance, Epidemiology, and End Results registries

  2012cited by this paper
• Drug Resistance in Glioblastoma: A Mini Review

  2012cited by this paper
• Restricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transporters P-gp and BCRP

  2012cited by this paper
• Current clinical development of PI3K pathway inhibitors in glioblastoma.

  2012cited by this paper
• Targeted radiotherapy for malignant gliomas.

  2012cited by this paper
• Examination of blood–brain barrier (BBB) integrity in a mouse brain tumor model

  2012cited by this paper
• Evidence of mTOR Activation by an AKT-Independent Mechanism Provides Support for the Combined Treatment of PTEN-Deficient Prostate Tumors with mTOR and AKT Inhibitors.

  2012cited by this paper
• Preclinical Assessment of the Absorption and Disposition of the Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor GDC-0980 and Prediction of Its Pharmacokinetics and Efficacy in Human

  2012influential reference
• Glycogen Synthase Kinase-3 is an Intermediate Modulator of Serotonin Neurotransmission

  2011cited by this paper
• Mechanisms and analysis of the CNS distribution of cediranib, a molecularly-targeted anti-angiogenic agent.

  2011cited by this paper
• Determination of cediranib in mouse plasma and brain tissue using high-performance liquid chromatography-mass spectrometry.

  2011cited by this paper
• Pathway inhibition: emerging molecular targets for treating glioblastoma.

  2011cited by this paper
• Treatment Resistance Mechanisms of Malignant Glioma Tumor Stem Cells

  2011cited by this paper
• The brain tumor microenvironment

  2011cited by this paper
• Phase II study of sunitinib malate in patients with recurrent high-grade glioma

  2011cited by this paper
• Establishment, Maintenance, and In Vitro and In Vivo Applications of Primary Human Glioblastoma Multiforme (GBM) Xenograft Models for Translational Biology Studies and Drug Discovery

  2011cited by this paper
• Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain

  2011influential reference
• Glioblastoma recurrence after cediranib therapy in patients: lack of "rebound" revascularization as mode of escape.

  2011cited by this paper
• The controversial role of ABC transporters in clinical oncology.

  2011cited by this paper
• Dual inhibitors of PI3K/mTOR or mTOR-selective inhibitors: which way shall we go?

  2011influential reference
• Breast cancer resistance protein and P-glycoprotein in brain cancer: two gatekeepers team up.

  2011influential reference
• The Role of the Breast Cancer Resistance Protein (ABCG2) in the Distribution of Sorafenib to the Brain

  2011cited by this paper
• EGFR Gene Overexpression Retained in an Invasive Xenograft Model by Solid Orthotopic Transplantation of Human Glioblastoma Multiforme Into Nude Mice

  2011cited by this paper
• Molecular targeting of glioblastoma: Drug discovery and therapies.

  2011cited by this paper
• Angiogenesis and invasion in glioma

  2011cited by this paper
• Aflibercept (VEGF-TRAP): the next anti-VEGF drug.

  2011cited by this paper
• The Hedgehog Pathway Promotes Blood-Brain Barrier Integrity and CNS Immune Quiescence

  2011cited by this paper
• Insulin Growth Factor-2 Binding Protein 3 (IGF2BP3) Is a Glioblastoma-specific Marker That Activates Phosphatidylinositol 3-Kinase/Mitogen-activated Protein Kinase (PI3K/MAPK) Pathways by Modulating IGF-2*

  2011cited by this paper
• Differential Impact of P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) on Axitinib Brain Accumulation and Oral Plasma Pharmacokinetics

  2011cited by this paper
• ABC transporters in cancer: more than just drug efflux pumps

  2010cited by this paper
• U87MG Decoded: The Genomic Sequence of a Cytogenetically Aberrant Human Cancer Cell Line

  2010cited by this paper
• Drug penetration across the blood-brain barrier: an overview.

  2010cited by this paper
• Development of PLGA nanoparticles simultaneously loaded with vincristine and verapamil for treatment of hepatocellular carcinoma.

  2010cited by this paper
• Targeted therapy for high-grade glioma with the TGF-β2 inhibitor trabedersen: results of a randomized and controlled phase IIb study

  2010cited by this paper
• Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases.

  2010cited by this paper
• Molecular Therapeutic Targets for Glioma Angiogenesis

  2010influential reference
• Distribution of Gefitinib to the Brain Is Limited by P-glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2)-Mediated Active Efflux

  2010cited by this paper
• Sorafenib exerts anti-glioma activity in vitro and in vivo.

  2010cited by this paper
• Structure and function of the blood-brain barrier.

  2010cited by this paper
• mTOR signaling in glioblastoma: lessons learned from bench to bedside

  2010influential reference
• Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts.

  2010cited by this paper
• Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma.

  2010influential reference
• Convection-enhanced delivery of free gadolinium with the recombinant immunotoxin MR1-1

  2010cited by this paper
• Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma.

  2010cited by this paper
• Molecular Mechanisms of Resistance to Tumour Anti-Angiogenic Strategies

  2010cited by this paper
• P-glycoprotein and breast cancer resistance protein affect disposition of tandutinib, a tyrosine kinase inhibitor.

  2010cited by this paper
• Breast Cancer Resistance Protein and P-glycoprotein Limit Sorafenib Brain Accumulation

  2010cited by this paper
• Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice

  2010cited by this paper
• Survival of Patients with Newly Diagnosed Glioblastoma Treated with Radiation and Temozolomide in Research Studies in the United States

  2010cited by this paper
• Bioanalytical method for the quantification of sunitinib and its n-desethyl metabolite SU12662 in human plasma by ultra performance liquid chromatography/tandem triple-quadrupole mass spectrometry.

  2010cited by this paper

• No citing papers are available for this paper.